Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab
2021 ASCO Annual Meeting
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
The ASCO Post Staff
Matt D. Galsky, MD, of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses results from a phase II trial designed to test gemcitabine and cisplatin plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to better predict benefit in those who opted out of cystectomy (Abstract 4503).
The ASCO Post Staff
Terry P. Mamounas, MD, MPH, of the University of Florida Health Cancer Center, discusses results from the NRG Oncology/NSABP B-42 study, which examined the Breast Cancer Index and its ability to predict whether extended treatment with letrozole benefits patients with hormone receptor–positive breast cancer (Abstract 501).
The ASCO Post Staff
Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung cancer tend to be less likely to undergo biomarker testing or to be treated in clinical trials than White patients. Recommended broad-based testing, says Dr. Bruno, may help ensure equal access to quality care and clinical trials (Abstract 9005).
The ASCO Post Staff
Linda R. Mileshkin, MBBS, MD, of the Peter MacCallum Cancer Centre, discusses phase III findings from the OUTBACK trial, which showed that adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve either overall or progression-free survival (Abstract LBA3).
The ASCO Post Staff
Melinda L. Telli, MD, of Stanford University, discusses results of a phase II study on neoadjuvant talazoparib in germline BRCA1/2 mutation–positive, early HER2-negative breast cancer. In this setting, talazoparib monotherapy was active and yielded pathologic complete response rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens (Abstract 505).